Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update
Ann Rheum Dis 2023; 2023-224762 DOI: 10.1136/ard-2023-224762 Epub ahead of print
The objective of this international task force was to update the EULAR recommendations for the management of SLE. The Task Force agreed on 5 overarching principles and 13 recommendations, generating an overall framework for the approach to a patient with SLE. The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.
Keywords:
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Changes in Discrete Subsets of Blood Transcriptomic and Cellular Biomarkers
Br J Dermatol. 2023 doi: 10.1093/bjd/ljad089
Prospective single-centre study of anifrolumab in refractory mucocutaneous SLE, indicates rapid efficacy of anifrolumab in discoid lupus erythematosus (DLE) and rituximab-resistant CLE.
Keywords:
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
Ann Rheum Dis. 2023 doi: 10.1136/ard-2022-223628
The first EULAR-endorsed points to consider (PtC) for the measurement and reporting of IFN-I assays in clinical research and practice are developed.
Baricitinib for Systemic Lupus Erythematosus: a Double-blind, Randomised, Placebo-controlled, Phase 3 Trial (SLE-BRAVE-I)
Lancet. 2023 doi: 10.1016/S0140-6736(22)02607-1
Primary endpoint in SLE-BRAVE-I study was met for the 4 mg baricitinib group, however, key secondary endpoints were not.
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Ann Rheum Dis. 2022; 0:1–11. doi: 10.1136/annrheumdis-2021-221425
IFN-I signalling plays a key role in SLE pathogenesis, and anifrolumab has demonstrated inhibitory effects on IFN-I signalling in patients with SLE. Vital, et al. characterised efficacy and safety of anifrolumab in patients with moderate-to-severe SLE based on interferon gene signature, demographic and clinical subgroups using data pooled from the Phase III TULIP-1 and -2 trials.
Efficacy and Safety of Obinutuzumab in Systemic Lupus Erythematosus Patients with Secondary Non-response to Rituximab
Rheumatology 2022;00:1–5 DOI.org/10.1093/rheumatology/keac150
Arnold, et al. present the first case series reporting the efficacy and safety of obinutuzumab in patients with treatment refractory SLE. The results indicate that, for this group of patients with limited treatment approaches, obinutuzumab could be a potential option.
Keywords:
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
Lancet Rheumatol. Published online February 3, 2022
Across two pivotal phase 3 trials (TULIP-1 and TULIP-2), anifrolumab treatment improved systemic lupus erythematosus (SLE) disease activity across multiple organ domains, compared with placebo.
Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index
Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keab883
Easy-BILAG is a high-accuracy, time-efficient tool for recording BILAG-2004 disease activity in systemic lupus erythematosus (SLE).
Disease activity measurements in SLE are necessary for optimal patient care, treat-to-target approaches and clinical guidelines. However, administrative burden and potential frequency of errors with the current comprehensive disease activity instrument (BILAG-2004) limits its use in routine practice.